Protagonist Therapeutics (PTGX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $8.09B, a trailing price-to-earnings ratio of 26.3 and a free-cash-flow yield of 0.7%. Over the most recent reported fiscal year, revenue declined 89.4% and free cash flow per share fell 68.6%. Nama's AI scorecard rates it Buy, 6.0 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Buy · 6.0/10
Positive, at the low end of Buy. As of Nov 20, 2026.
Momentum
Leading · +64.0% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-24.5%
How far the last close sits under the highest price of the past five years.
Market cap
$8.09B
Trailing P/E
26.3
Price / book
7.5
Price / sales
14.7
FCF yield
0.7%
Dividend yield
—
Gross margin
99.8%
Operating margin
58.6%
Net margin
62.0%
Revenue growth (YoY)
-89.4%
Revenue growth (3-yr annual)
+20.1%
EPS growth (YoY)
-148.8%
FCF/share growth (YoY)
-68.6%
Beta
1.2
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
PTGX earnings
Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.22).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 5, 2026
$3.07
$2.66
+15.4%
$274.41M
Q2 2026
Aug 5, 2026
$2.29
$1.94
+18.0%
$213.47M
Q1 2026
May 5, 2026
$0.05
-$0.65
+107.7%
$56.37M
Q4 2025
Feb 25, 2026
-$0.69
-$0.54
-27.8%
$7.44M
PTGX analyst price target
Median target $181.00 from 14 analysts, ranging $151.00 – $225.00.
Nama's AI scorecard currently rates Protagonist Therapeutics Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PTGX's P/E ratio?
Protagonist Therapeutics trades at a trailing price-to-earnings ratio of 26.3.
When does PTGX report earnings?
Protagonist Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.22.
What is the PTGX price target?
The median analyst price target from 14 analysts is $181.00, with a range of $151.00 – $225.00.
Is PTGX Shariah compliant?
Nama's AAOIFI-style screen reads Protagonist Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.